Business
Boundless Bio Announces Departure of Chief Financial Officer
SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA)
About this update from Boundless Bio, Inc.
[{"type":"text","content":"SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Jami Rubin has stepped down from her role as Chief Financial Officer (CFO) for personal reasons. Boundless Bio does not plan to hire a successor CFO at this time; David Hinkle, Senior Vice President, Finance and Controller, will maintain responsibility for the company’s Finance operations and assume the roles of principal financial and accounting officer. “On behalf of the company and Board, I want to extend my sincerest gratitude to Jami for her many contributions during her tenure at Boundless, including her leadership in the success of our IPO and the refinement of our corporate strategy,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “Thanks to Jami’s contributions, Boundless is in a strong position for the future and we wish her all the best.” “It has been an honor to serve in this position, and I take great pride in what we have accomplished at Boundless on our journey to become a leader in developing drugs to treat patients with oncogene amplified cancers,” said Ms. Rubin. “A hallmark of my time at Boundless has been collaborating with such a talented team and supportive Board. With the clinical trials underway for our lead programs and a balance sheet that supports their continued advancement, I am confident that Boundless is positioned for success.” About Boundless BioBoundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapeutic candidate (ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1 (CHK1) being evaluated in a Phase 1/2 clinical trial in patients with oncogene amplified cancers. Boundless Bio’s second ecDTx, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) being evaluated in a Phase 1/2 clinical trial in cancer patients with resistance gene amplifications...